nodes	percent_of_prediction	percent_of_DWPC	metapath
Disopyramide—ORM1—Vemurafenib—melanoma	0.503	0.705	CbGbCtD
Disopyramide—CYP3A4—Temozolomide—melanoma	0.121	0.17	CbGbCtD
Disopyramide—CYP3A4—Vemurafenib—melanoma	0.0664	0.093	CbGbCtD
Disopyramide—CYP3A4—Docetaxel—melanoma	0.0228	0.0319	CbGbCtD
Disopyramide—Rash generalised—Vemurafenib—melanoma	0.00759	0.0583	CcSEcCtD
Disopyramide—Lupus erythematosus—Docetaxel—melanoma	0.00294	0.0226	CcSEcCtD
Disopyramide—Rash generalised—Docetaxel—melanoma	0.00258	0.0198	CcSEcCtD
Disopyramide—Systemic lupus erythematosus—Docetaxel—melanoma	0.00198	0.0152	CcSEcCtD
Disopyramide—Hepatic enzyme increased—Temozolomide—melanoma	0.00174	0.0134	CcSEcCtD
Disopyramide—Haemoglobin decreased—Docetaxel—melanoma	0.00159	0.0122	CcSEcCtD
Disopyramide—Coma—Carmustine—melanoma	0.00156	0.012	CcSEcCtD
Disopyramide—Gynaecomastia—Carmustine—melanoma	0.00153	0.0117	CcSEcCtD
Disopyramide—Dry eye—Temozolomide—melanoma	0.00152	0.0117	CcSEcCtD
Disopyramide—Dysgeusia—Vemurafenib—melanoma	0.00138	0.0106	CcSEcCtD
Disopyramide—Diplopia—Carmustine—melanoma	0.00124	0.00951	CcSEcCtD
Disopyramide—Diplopia—Temozolomide—melanoma	0.0012	0.00919	CcSEcCtD
Disopyramide—Hypokalaemia—Carmustine—melanoma	0.00113	0.00866	CcSEcCtD
Disopyramide—Skin disorder—Vemurafenib—melanoma	0.00112	0.00859	CcSEcCtD
Disopyramide—Muscular weakness—Carmustine—melanoma	0.00109	0.00839	CcSEcCtD
Disopyramide—Hypokalaemia—Temozolomide—melanoma	0.00109	0.00837	CcSEcCtD
Disopyramide—Hypotension—Vemurafenib—melanoma	0.00108	0.00826	CcSEcCtD
Disopyramide—Neutropenia—Dactinomycin—melanoma	0.00107	0.00821	CcSEcCtD
Disopyramide—Muscular weakness—Temozolomide—melanoma	0.00106	0.00811	CcSEcCtD
Disopyramide—Abdominal distension—Temozolomide—melanoma	0.00104	0.008	CcSEcCtD
Disopyramide—Sweating increased—Temozolomide—melanoma	0.00101	0.00774	CcSEcCtD
Disopyramide—Neutropenia—Carmustine—melanoma	0.001	0.00769	CcSEcCtD
Disopyramide—Decreased appetite—Vemurafenib—melanoma	0.001	0.00769	CcSEcCtD
Disopyramide—Fatigue—Vemurafenib—melanoma	0.000992	0.00762	CcSEcCtD
Disopyramide—Constipation—Vemurafenib—melanoma	0.000984	0.00756	CcSEcCtD
Disopyramide—Hypoaesthesia—Bleomycin—melanoma	0.000977	0.0075	CcSEcCtD
Disopyramide—Dysuria—Temozolomide—melanoma	0.000967	0.00743	CcSEcCtD
Disopyramide—Neutropenia—Temozolomide—melanoma	0.000967	0.00743	CcSEcCtD
Disopyramide—Pollakiuria—Temozolomide—melanoma	0.000956	0.00734	CcSEcCtD
Disopyramide—Erectile dysfunction—Temozolomide—melanoma	0.000953	0.00732	CcSEcCtD
Disopyramide—Depression—Carmustine—melanoma	0.000952	0.00731	CcSEcCtD
Disopyramide—Agranulocytosis—Dactinomycin—melanoma	0.000952	0.00731	CcSEcCtD
Disopyramide—Weight increased—Temozolomide—melanoma	0.000941	0.00723	CcSEcCtD
Disopyramide—Depression—Temozolomide—melanoma	0.00092	0.00706	CcSEcCtD
Disopyramide—Hepatitis—Dactinomycin—melanoma	0.000916	0.00703	CcSEcCtD
Disopyramide—Body temperature increased—Vemurafenib—melanoma	0.00091	0.00699	CcSEcCtD
Disopyramide—Cardiac failure congestive—Docetaxel—melanoma	0.000878	0.00674	CcSEcCtD
Disopyramide—Hypoaesthesia—Carmustine—melanoma	0.000853	0.00655	CcSEcCtD
Disopyramide—Hepatitis—Temozolomide—melanoma	0.000828	0.00636	CcSEcCtD
Disopyramide—Asthenia—Vemurafenib—melanoma	0.000826	0.00634	CcSEcCtD
Disopyramide—Hypoaesthesia—Temozolomide—melanoma	0.000824	0.00633	CcSEcCtD
Disopyramide—Cardiac failure—Docetaxel—melanoma	0.000816	0.00626	CcSEcCtD
Disopyramide—Pruritus—Vemurafenib—melanoma	0.000814	0.00625	CcSEcCtD
Disopyramide—Ill-defined disorder—Bleomycin—melanoma	0.000793	0.00609	CcSEcCtD
Disopyramide—Diarrhoea—Vemurafenib—melanoma	0.000788	0.00605	CcSEcCtD
Disopyramide—Malaise—Bleomycin—melanoma	0.000771	0.00592	CcSEcCtD
Disopyramide—Arrhythmia—Carmustine—melanoma	0.000765	0.00588	CcSEcCtD
Disopyramide—Dizziness—Vemurafenib—melanoma	0.000761	0.00585	CcSEcCtD
Disopyramide—Ill-defined disorder—Dactinomycin—melanoma	0.000739	0.00568	CcSEcCtD
Disopyramide—Vomiting—Vemurafenib—melanoma	0.000732	0.00562	CcSEcCtD
Disopyramide—Chest pain—Bleomycin—melanoma	0.000728	0.00559	CcSEcCtD
Disopyramide—Abdominal pain upper—Docetaxel—melanoma	0.000727	0.00558	CcSEcCtD
Disopyramide—Rash—Vemurafenib—melanoma	0.000726	0.00557	CcSEcCtD
Disopyramide—Dermatitis—Vemurafenib—melanoma	0.000725	0.00557	CcSEcCtD
Disopyramide—Headache—Vemurafenib—melanoma	0.000721	0.00554	CcSEcCtD
Disopyramide—Discomfort—Bleomycin—melanoma	0.000719	0.00552	CcSEcCtD
Disopyramide—Malaise—Dactinomycin—melanoma	0.000719	0.00552	CcSEcCtD
Disopyramide—Dysgeusia—Temozolomide—melanoma	0.000706	0.00542	CcSEcCtD
Disopyramide—Confusional state—Bleomycin—melanoma	0.000703	0.0054	CcSEcCtD
Disopyramide—Vision blurred—Carmustine—melanoma	0.000703	0.0054	CcSEcCtD
Disopyramide—Oedema—Bleomycin—melanoma	0.000697	0.00536	CcSEcCtD
Disopyramide—Nausea—Vemurafenib—melanoma	0.000684	0.00525	CcSEcCtD
Disopyramide—Thrombocytopenia—Bleomycin—melanoma	0.000683	0.00524	CcSEcCtD
Disopyramide—Vision blurred—Temozolomide—melanoma	0.000679	0.00522	CcSEcCtD
Disopyramide—Discomfort—Dactinomycin—melanoma	0.00067	0.00515	CcSEcCtD
Disopyramide—Ill-defined disorder—Temozolomide—melanoma	0.000669	0.00514	CcSEcCtD
Disopyramide—Anorexia—Bleomycin—melanoma	0.000665	0.00511	CcSEcCtD
Disopyramide—Angioedema—Temozolomide—melanoma	0.000659	0.00506	CcSEcCtD
Disopyramide—Hypotension—Bleomycin—melanoma	0.000652	0.005	CcSEcCtD
Disopyramide—Oedema—Dactinomycin—melanoma	0.00065	0.005	CcSEcCtD
Disopyramide—Malaise—Temozolomide—melanoma	0.00065	0.00499	CcSEcCtD
Disopyramide—Vertigo—Temozolomide—melanoma	0.000648	0.00497	CcSEcCtD
Disopyramide—Neutropenia—Docetaxel—melanoma	0.000643	0.00494	CcSEcCtD
Disopyramide—Thrombocytopenia—Dactinomycin—melanoma	0.000637	0.00489	CcSEcCtD
Disopyramide—Chest pain—Carmustine—melanoma	0.000635	0.00488	CcSEcCtD
Disopyramide—Paraesthesia—Bleomycin—melanoma	0.000626	0.00481	CcSEcCtD
Disopyramide—Weight increased—Docetaxel—melanoma	0.000626	0.00481	CcSEcCtD
Disopyramide—Dyspnoea—Bleomycin—melanoma	0.000622	0.00478	CcSEcCtD
Disopyramide—Anorexia—Dactinomycin—melanoma	0.00062	0.00476	CcSEcCtD
Disopyramide—Confusional state—Carmustine—melanoma	0.000614	0.00471	CcSEcCtD
Disopyramide—Oedema—Carmustine—melanoma	0.000609	0.00468	CcSEcCtD
Disopyramide—Discomfort—Temozolomide—melanoma	0.000606	0.00466	CcSEcCtD
Disopyramide—Decreased appetite—Bleomycin—melanoma	0.000606	0.00466	CcSEcCtD
Disopyramide—Dry mouth—Temozolomide—melanoma	0.0006	0.00461	CcSEcCtD
Disopyramide—Pain—Bleomycin—melanoma	0.000596	0.00458	CcSEcCtD
Disopyramide—Thrombocytopenia—Carmustine—melanoma	0.000596	0.00458	CcSEcCtD
Disopyramide—Confusional state—Temozolomide—melanoma	0.000593	0.00456	CcSEcCtD
Disopyramide—Oedema—Temozolomide—melanoma	0.000588	0.00452	CcSEcCtD
Disopyramide—Anorexia—Carmustine—melanoma	0.00058	0.00446	CcSEcCtD
Disopyramide—Thrombocytopenia—Temozolomide—melanoma	0.000576	0.00442	CcSEcCtD
Disopyramide—Feeling abnormal—Bleomycin—melanoma	0.000575	0.00441	CcSEcCtD
Disopyramide—Agranulocytosis—Docetaxel—melanoma	0.000572	0.0044	CcSEcCtD
Disopyramide—Skin disorder—Temozolomide—melanoma	0.000571	0.00439	CcSEcCtD
Disopyramide—Hypotension—Carmustine—melanoma	0.000569	0.00437	CcSEcCtD
Disopyramide—Hyperhidrosis—Temozolomide—melanoma	0.000569	0.00437	CcSEcCtD
Disopyramide—Decreased appetite—Dactinomycin—melanoma	0.000565	0.00434	CcSEcCtD
Disopyramide—Fatigue—Dactinomycin—melanoma	0.000561	0.00431	CcSEcCtD
Disopyramide—Anorexia—Temozolomide—melanoma	0.000561	0.00431	CcSEcCtD
Disopyramide—Pain—Dactinomycin—melanoma	0.000556	0.00427	CcSEcCtD
Disopyramide—Urticaria—Bleomycin—melanoma	0.000554	0.00426	CcSEcCtD
Disopyramide—Body temperature increased—Bleomycin—melanoma	0.000551	0.00423	CcSEcCtD
Disopyramide—Hepatitis—Docetaxel—melanoma	0.000551	0.00423	CcSEcCtD
Disopyramide—Insomnia—Carmustine—melanoma	0.000551	0.00423	CcSEcCtD
Disopyramide—Hypoaesthesia—Docetaxel—melanoma	0.000548	0.00421	CcSEcCtD
Disopyramide—Paraesthesia—Carmustine—melanoma	0.000547	0.0042	CcSEcCtD
Disopyramide—Dyspnoea—Carmustine—melanoma	0.000543	0.00417	CcSEcCtD
Disopyramide—Somnolence—Carmustine—melanoma	0.000541	0.00416	CcSEcCtD
Disopyramide—Feeling abnormal—Dactinomycin—melanoma	0.000536	0.00412	CcSEcCtD
Disopyramide—Insomnia—Temozolomide—melanoma	0.000532	0.00409	CcSEcCtD
Disopyramide—Decreased appetite—Carmustine—melanoma	0.000529	0.00406	CcSEcCtD
Disopyramide—Paraesthesia—Temozolomide—melanoma	0.000528	0.00406	CcSEcCtD
Disopyramide—Dyspnoea—Temozolomide—melanoma	0.000524	0.00403	CcSEcCtD
Disopyramide—Somnolence—Temozolomide—melanoma	0.000523	0.00402	CcSEcCtD
Disopyramide—Pain—Carmustine—melanoma	0.000521	0.004	CcSEcCtD
Disopyramide—Constipation—Carmustine—melanoma	0.000521	0.004	CcSEcCtD
Disopyramide—Dyspepsia—Temozolomide—melanoma	0.000518	0.00398	CcSEcCtD
Disopyramide—Body temperature increased—Dactinomycin—melanoma	0.000514	0.00395	CcSEcCtD
Disopyramide—Decreased appetite—Temozolomide—melanoma	0.000511	0.00393	CcSEcCtD
Disopyramide—Fatigue—Temozolomide—melanoma	0.000507	0.0039	CcSEcCtD
Disopyramide—Pain—Temozolomide—melanoma	0.000503	0.00386	CcSEcCtD
Disopyramide—Constipation—Temozolomide—melanoma	0.000503	0.00386	CcSEcCtD
Disopyramide—Feeling abnormal—Carmustine—melanoma	0.000502	0.00385	CcSEcCtD
Disopyramide—Asthenia—Bleomycin—melanoma	0.0005	0.00384	CcSEcCtD
Disopyramide—Pruritus—Bleomycin—melanoma	0.000493	0.00379	CcSEcCtD
Disopyramide—Arrhythmia—Docetaxel—melanoma	0.000492	0.00378	CcSEcCtD
Disopyramide—Feeling abnormal—Temozolomide—melanoma	0.000485	0.00372	CcSEcCtD
Disopyramide—Body temperature increased—Carmustine—melanoma	0.000481	0.0037	CcSEcCtD
Disopyramide—Dysgeusia—Docetaxel—melanoma	0.000469	0.00361	CcSEcCtD
Disopyramide—Urticaria—Temozolomide—melanoma	0.000467	0.00359	CcSEcCtD
Disopyramide—Asthenia—Dactinomycin—melanoma	0.000467	0.00358	CcSEcCtD
Disopyramide—Body temperature increased—Temozolomide—melanoma	0.000465	0.00357	CcSEcCtD
Disopyramide—Diarrhoea—Dactinomycin—melanoma	0.000445	0.00342	CcSEcCtD
Disopyramide—Vomiting—Bleomycin—melanoma	0.000443	0.00341	CcSEcCtD
Disopyramide—Rash—Bleomycin—melanoma	0.00044	0.00338	CcSEcCtD
Disopyramide—Dermatitis—Bleomycin—melanoma	0.000439	0.00337	CcSEcCtD
Disopyramide—Asthenia—Carmustine—melanoma	0.000437	0.00335	CcSEcCtD
Disopyramide—Syncope—Docetaxel—melanoma	0.00043	0.0033	CcSEcCtD
Disopyramide—Asthenia—Temozolomide—melanoma	0.000422	0.00324	CcSEcCtD
Disopyramide—Loss of consciousness—Docetaxel—melanoma	0.000421	0.00324	CcSEcCtD
Disopyramide—Diarrhoea—Carmustine—melanoma	0.000417	0.0032	CcSEcCtD
Disopyramide—Pruritus—Temozolomide—melanoma	0.000416	0.0032	CcSEcCtD
Disopyramide—Nausea—Bleomycin—melanoma	0.000414	0.00318	CcSEcCtD
Disopyramide—Vomiting—Dactinomycin—melanoma	0.000414	0.00318	CcSEcCtD
Disopyramide—Rash—Dactinomycin—melanoma	0.00041	0.00315	CcSEcCtD
Disopyramide—Chest pain—Docetaxel—melanoma	0.000408	0.00313	CcSEcCtD
Disopyramide—Dizziness—Carmustine—melanoma	0.000403	0.00309	CcSEcCtD
Disopyramide—Diarrhoea—Temozolomide—melanoma	0.000403	0.00309	CcSEcCtD
Disopyramide—Dry mouth—Docetaxel—melanoma	0.000399	0.00307	CcSEcCtD
Disopyramide—Confusional state—Docetaxel—melanoma	0.000394	0.00303	CcSEcCtD
Disopyramide—Oedema—Docetaxel—melanoma	0.000391	0.003	CcSEcCtD
Disopyramide—Dizziness—Temozolomide—melanoma	0.000389	0.00299	CcSEcCtD
Disopyramide—Vomiting—Carmustine—melanoma	0.000387	0.00297	CcSEcCtD
Disopyramide—Nausea—Dactinomycin—melanoma	0.000386	0.00297	CcSEcCtD
Disopyramide—Shock—Docetaxel—melanoma	0.000385	0.00296	CcSEcCtD
Disopyramide—Rash—Carmustine—melanoma	0.000384	0.00295	CcSEcCtD
Disopyramide—Dermatitis—Carmustine—melanoma	0.000383	0.00295	CcSEcCtD
Disopyramide—Thrombocytopenia—Docetaxel—melanoma	0.000383	0.00294	CcSEcCtD
Disopyramide—Headache—Carmustine—melanoma	0.000381	0.00293	CcSEcCtD
Disopyramide—Skin disorder—Docetaxel—melanoma	0.00038	0.00292	CcSEcCtD
Disopyramide—Vomiting—Temozolomide—melanoma	0.000374	0.00287	CcSEcCtD
Disopyramide—Anorexia—Docetaxel—melanoma	0.000373	0.00286	CcSEcCtD
Disopyramide—Rash—Temozolomide—melanoma	0.000371	0.00285	CcSEcCtD
Disopyramide—Dermatitis—Temozolomide—melanoma	0.000371	0.00285	CcSEcCtD
Disopyramide—Headache—Temozolomide—melanoma	0.000369	0.00283	CcSEcCtD
Disopyramide—Hypotension—Docetaxel—melanoma	0.000366	0.00281	CcSEcCtD
Disopyramide—Nausea—Carmustine—melanoma	0.000362	0.00278	CcSEcCtD
Disopyramide—Insomnia—Docetaxel—melanoma	0.000354	0.00272	CcSEcCtD
Disopyramide—Paraesthesia—Docetaxel—melanoma	0.000351	0.0027	CcSEcCtD
Disopyramide—Nausea—Temozolomide—melanoma	0.000349	0.00268	CcSEcCtD
Disopyramide—Dyspnoea—Docetaxel—melanoma	0.000349	0.00268	CcSEcCtD
Disopyramide—Somnolence—Docetaxel—melanoma	0.000348	0.00267	CcSEcCtD
Disopyramide—Dyspepsia—Docetaxel—melanoma	0.000344	0.00264	CcSEcCtD
Disopyramide—Decreased appetite—Docetaxel—melanoma	0.00034	0.00261	CcSEcCtD
Disopyramide—Fatigue—Docetaxel—melanoma	0.000337	0.00259	CcSEcCtD
Disopyramide—Pain—Docetaxel—melanoma	0.000335	0.00257	CcSEcCtD
Disopyramide—Constipation—Docetaxel—melanoma	0.000335	0.00257	CcSEcCtD
Disopyramide—Feeling abnormal—Docetaxel—melanoma	0.000322	0.00248	CcSEcCtD
Disopyramide—Body temperature increased—Docetaxel—melanoma	0.000309	0.00238	CcSEcCtD
Disopyramide—Asthenia—Docetaxel—melanoma	0.000281	0.00216	CcSEcCtD
Disopyramide—Pruritus—Docetaxel—melanoma	0.000277	0.00213	CcSEcCtD
Disopyramide—Diarrhoea—Docetaxel—melanoma	0.000268	0.00206	CcSEcCtD
Disopyramide—Dizziness—Docetaxel—melanoma	0.000259	0.00199	CcSEcCtD
Disopyramide—Vomiting—Docetaxel—melanoma	0.000249	0.00191	CcSEcCtD
Disopyramide—Rash—Docetaxel—melanoma	0.000247	0.00189	CcSEcCtD
Disopyramide—Dermatitis—Docetaxel—melanoma	0.000246	0.00189	CcSEcCtD
Disopyramide—Headache—Docetaxel—melanoma	0.000245	0.00188	CcSEcCtD
Disopyramide—Nausea—Docetaxel—melanoma	0.000232	0.00178	CcSEcCtD
Disopyramide—CHRM1—GPCR downstream signaling—CXCL8—melanoma	1.8e-05	0.000115	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CD86—melanoma	1.79e-05	0.000115	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—CXCL8—melanoma	1.79e-05	0.000115	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EDN1—melanoma	1.78e-05	0.000114	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EDN1—melanoma	1.78e-05	0.000114	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CD86—melanoma	1.77e-05	0.000114	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—CXCL8—melanoma	1.77e-05	0.000113	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EDN1—melanoma	1.76e-05	0.000113	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PPARG—melanoma	1.75e-05	0.000112	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FGF1—melanoma	1.74e-05	0.000112	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CSF2—melanoma	1.74e-05	0.000112	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FGF1—melanoma	1.74e-05	0.000111	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CSF2—melanoma	1.74e-05	0.000111	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FGF1—melanoma	1.72e-05	0.00011	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CSF2—melanoma	1.72e-05	0.00011	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—IL2—melanoma	1.72e-05	0.00011	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—IL2—melanoma	1.71e-05	0.00011	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—E2F1—melanoma	1.7e-05	0.000109	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—E2F1—melanoma	1.7e-05	0.000109	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—PIK3CB—melanoma	1.7e-05	0.000109	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—IL2—melanoma	1.69e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—PIK3CB—melanoma	1.69e-05	0.000108	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CG—melanoma	1.69e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PDGFRA—melanoma	1.69e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—E2F1—melanoma	1.68e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PDGFRA—melanoma	1.68e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CB—melanoma	1.68e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ITGB3—melanoma	1.67e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PRKCA—melanoma	1.67e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PDGFRA—melanoma	1.67e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PRKCA—melanoma	1.66e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ITGB3—melanoma	1.66e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ITGB3—melanoma	1.65e-05	0.000106	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PRKCA—melanoma	1.65e-05	0.000106	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SPP1—melanoma	1.64e-05	0.000105	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAP2K2—melanoma	1.63e-05	0.000105	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SPP1—melanoma	1.63e-05	0.000105	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—CXCL8—melanoma	1.63e-05	0.000104	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PPARG—melanoma	1.63e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAP2K2—melanoma	1.63e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—CXCL8—melanoma	1.63e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SPP1—melanoma	1.62e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAP2K2—melanoma	1.61e-05	0.000103	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PLA2G6—melanoma	1.61e-05	0.000103	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—CXCL8—melanoma	1.61e-05	0.000103	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CD—melanoma	1.59e-05	0.000102	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—ALB—melanoma	1.57e-05	0.000101	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CG—melanoma	1.56e-05	9.98e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL2—melanoma	1.56e-05	9.98e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL2—melanoma	1.55e-05	9.95e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TERT—melanoma	1.55e-05	9.94e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—RAC1—melanoma	1.55e-05	9.91e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TERT—melanoma	1.55e-05	9.91e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—RAC1—melanoma	1.54e-05	9.88e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL2—melanoma	1.54e-05	9.85e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TERT—melanoma	1.53e-05	9.81e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—RAC1—melanoma	1.53e-05	9.79e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PPARG—melanoma	1.51e-05	9.64e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HIF1A—melanoma	1.49e-05	9.51e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CD—melanoma	1.48e-05	9.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HIF1A—melanoma	1.48e-05	9.48e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HIF1A—melanoma	1.47e-05	9.38e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—ALB—melanoma	1.47e-05	9.38e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—VCAN—melanoma	1.45e-05	9.26e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KDR—melanoma	1.42e-05	9.09e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KDR—melanoma	1.42e-05	9.06e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KDR—melanoma	1.4e-05	8.97e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CB—melanoma	1.39e-05	8.89e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTGS2—melanoma	1.38e-05	8.8e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CD—melanoma	1.37e-05	8.78e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FN1—melanoma	1.37e-05	8.75e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FN1—melanoma	1.36e-05	8.72e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—ALB—melanoma	1.35e-05	8.66e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FN1—melanoma	1.35e-05	8.64e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NOTCH1—melanoma	1.34e-05	8.56e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NOTCH1—melanoma	1.33e-05	8.54e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NOTCH1—melanoma	1.32e-05	8.45e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CD80—melanoma	1.31e-05	8.39e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CG—melanoma	1.31e-05	8.38e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—APC—melanoma	1.31e-05	8.38e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KIT—melanoma	1.31e-05	8.38e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—NRAS—melanoma	1.31e-05	8.38e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CD80—melanoma	1.31e-05	8.36e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KIT—melanoma	1.3e-05	8.35e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—APC—melanoma	1.3e-05	8.35e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CG—melanoma	1.3e-05	8.35e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—NRAS—melanoma	1.3e-05	8.35e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CD80—melanoma	1.29e-05	8.28e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CB—melanoma	1.29e-05	8.28e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EGF—melanoma	1.29e-05	8.28e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—APC—melanoma	1.29e-05	8.27e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KIT—melanoma	1.29e-05	8.27e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CG—melanoma	1.29e-05	8.27e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—NRAS—melanoma	1.29e-05	8.27e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EGF—melanoma	1.29e-05	8.25e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTGS2—melanoma	1.28e-05	8.21e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EGF—melanoma	1.28e-05	8.17e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—MAPK3—melanoma	1.25e-05	8.02e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—MAPK3—melanoma	1.25e-05	8e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—MAPK3—melanoma	1.24e-05	7.92e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—BRAF—melanoma	1.23e-05	7.87e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—BRAF—melanoma	1.23e-05	7.85e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP17A1—melanoma	1.22e-05	7.81e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—BRAF—melanoma	1.21e-05	7.77e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTEN—melanoma	1.2e-05	7.68e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IGF1—melanoma	1.2e-05	7.67e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CB—melanoma	1.2e-05	7.65e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IGF1—melanoma	1.19e-05	7.64e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—MAPK1—melanoma	1.19e-05	7.63e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—EGFR—melanoma	1.19e-05	7.63e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—MAPK1—melanoma	1.19e-05	7.61e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—EGFR—melanoma	1.19e-05	7.61e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTGS2—melanoma	1.18e-05	7.58e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IGF1—melanoma	1.18e-05	7.57e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—MAPK1—melanoma	1.18e-05	7.53e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—EGFR—melanoma	1.18e-05	7.53e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAP2K1—melanoma	1.16e-05	7.41e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAP2K1—melanoma	1.15e-05	7.39e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GNA11—melanoma	1.15e-05	7.38e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CD—melanoma	1.15e-05	7.36e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CD—melanoma	1.15e-05	7.34e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAP2K1—melanoma	1.14e-05	7.32e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	1.14e-05	7.29e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—PIK3CA—melanoma	1.14e-05	7.27e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CD—melanoma	1.14e-05	7.27e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—FASN—melanoma	1.13e-05	7.22e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—KRAS—melanoma	1.13e-05	7.21e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—PIK3CA—melanoma	1.12e-05	7.2e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—KRAS—melanoma	1.12e-05	7.19e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTEN—melanoma	1.12e-05	7.16e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—KRAS—melanoma	1.11e-05	7.12e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SLC5A5—melanoma	1.11e-05	7.1e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FGF2—melanoma	1.1e-05	7.05e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FGF2—melanoma	1.1e-05	7.03e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FGF2—melanoma	1.09e-05	6.96e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GNAQ—melanoma	1.07e-05	6.86e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CD44—melanoma	1.07e-05	6.86e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—PIK3CA—melanoma	1.03e-05	6.62e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTEN—melanoma	1.03e-05	6.61e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—PIK3CA—melanoma	1.03e-05	6.6e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MDM2—melanoma	1.03e-05	6.6e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP1B1—melanoma	1.03e-05	6.58e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MDM2—melanoma	1.03e-05	6.58e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CA—melanoma	1.02e-05	6.54e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MDM2—melanoma	1.02e-05	6.51e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ERBB2—melanoma	1.02e-05	6.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ERBB2—melanoma	1.01e-05	6.48e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ERBB2—melanoma	1e-05	6.42e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CB—melanoma	1e-05	6.42e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CB—melanoma	9.99e-06	6.4e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CB—melanoma	9.9e-06	6.34e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CXCL8—melanoma	9.63e-06	6.17e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CXCL8—melanoma	9.6e-06	6.15e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—HRAS—melanoma	9.57e-06	6.13e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—HRAS—melanoma	9.54e-06	6.11e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CXCL8—melanoma	9.51e-06	6.09e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—HRAS—melanoma	9.45e-06	6.05e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CDKN1B—melanoma	9.41e-06	6.02e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CDKN1B—melanoma	9.38e-06	6e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—AKT1—melanoma	9.31e-06	5.96e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CDKN1B—melanoma	9.29e-06	5.95e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—AKT1—melanoma	9.28e-06	5.94e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CASP3—melanoma	9.22e-06	5.9e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL2—melanoma	9.21e-06	5.89e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CASP3—melanoma	9.19e-06	5.88e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—AKT1—melanoma	9.19e-06	5.88e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL2—melanoma	9.18e-06	5.88e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL6—melanoma	9.16e-06	5.86e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL6—melanoma	9.13e-06	5.85e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CASP3—melanoma	9.1e-06	5.83e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL2—melanoma	9.09e-06	5.82e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL6—melanoma	9.04e-06	5.79e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CCND1—melanoma	8.97e-06	5.75e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CCND1—melanoma	8.95e-06	5.73e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CTNNB1—melanoma	8.89e-06	5.69e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCND1—melanoma	8.86e-06	5.67e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CTNNB1—melanoma	8.86e-06	5.67e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CTNNB1—melanoma	8.77e-06	5.62e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MMP9—melanoma	8.71e-06	5.58e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MMP9—melanoma	8.69e-06	5.56e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CDKN1A—melanoma	8.68e-06	5.56e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PTEN—melanoma	8.66e-06	5.55e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CDKN1A—melanoma	8.65e-06	5.54e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PTEN—melanoma	8.63e-06	5.53e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NFKB1—melanoma	8.62e-06	5.52e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MMP9—melanoma	8.6e-06	5.51e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NFKB1—melanoma	8.59e-06	5.5e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CDKN1A—melanoma	8.57e-06	5.49e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PTEN—melanoma	8.55e-06	5.47e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NFKB1—melanoma	8.51e-06	5.45e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CA—melanoma	8.46e-06	5.42e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCB1—melanoma	8.46e-06	5.41e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—AKT1—melanoma	8.45e-06	5.41e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—AKT1—melanoma	8.42e-06	5.39e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—AKT1—melanoma	8.34e-06	5.34e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CA—melanoma	7.89e-06	5.05e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—VEGFA—melanoma	7.82e-06	5.01e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—VEGFA—melanoma	7.8e-06	4.99e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PRKCA—melanoma	7.78e-06	4.98e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—STAT3—melanoma	7.75e-06	4.96e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NRAS—melanoma	7.73e-06	4.95e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—VEGFA—melanoma	7.72e-06	4.94e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—STAT3—melanoma	7.72e-06	4.94e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ERCC2—melanoma	7.72e-06	4.94e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NRAS—melanoma	7.7e-06	4.93e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—STAT3—melanoma	7.65e-06	4.9e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NRAS—melanoma	7.63e-06	4.88e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK3—melanoma	7.4e-06	4.74e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK3—melanoma	7.38e-06	4.72e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK3—melanoma	7.31e-06	4.68e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CA—melanoma	7.29e-06	4.66e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MYC—melanoma	7.2e-06	4.61e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MYC—melanoma	7.18e-06	4.59e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MYC—melanoma	7.11e-06	4.55e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK1—melanoma	7.04e-06	4.51e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EGFR—melanoma	7.04e-06	4.51e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK1—melanoma	7.02e-06	4.49e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EGFR—melanoma	7.02e-06	4.49e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK1—melanoma	6.95e-06	4.45e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EGFR—melanoma	6.95e-06	4.45e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—AKT1—melanoma	6.91e-06	4.43e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KRAS—melanoma	6.65e-06	4.26e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KRAS—melanoma	6.63e-06	4.24e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KRAS—melanoma	6.57e-06	4.2e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—AKT1—melanoma	6.44e-06	4.12e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CA—melanoma	6.11e-06	3.91e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CG—melanoma	6.1e-06	3.9e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CA—melanoma	6.09e-06	3.9e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CA—melanoma	6.03e-06	3.86e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—AKT1—melanoma	5.95e-06	3.81e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TP53—melanoma	5.91e-06	3.78e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TP53—melanoma	5.89e-06	3.77e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PPARG—melanoma	5.88e-06	3.77e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TP53—melanoma	5.84e-06	3.74e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HRAS—melanoma	5.65e-06	3.62e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HRAS—melanoma	5.64e-06	3.61e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HRAS—melanoma	5.58e-06	3.57e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL6—melanoma	5.41e-06	3.46e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL6—melanoma	5.39e-06	3.45e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CD—melanoma	5.36e-06	3.43e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL6—melanoma	5.34e-06	3.42e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALB—melanoma	5.29e-06	3.39e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AKT1—melanoma	4.99e-06	3.2e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AKT1—melanoma	4.98e-06	3.19e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AKT1—melanoma	4.93e-06	3.15e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CB—melanoma	4.67e-06	2.99e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTGS2—melanoma	4.63e-06	2.96e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTEN—melanoma	4.04e-06	2.58e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CA—melanoma	2.85e-06	1.82e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—AKT1—melanoma	2.33e-06	1.49e-05	CbGpPWpGaD
